In a study published in the journal Leukemia, lead author Ami Patel, MD, Huntsman Cancer Institute researcher and assistant professor in the Division of Hematology and Hematologic Malignancies at the University of Utah, showed that factors produced by bone marrow support cells allowed leukemia cells to survive treatment with quizartinib, a type of TKI. When quizartinib was combined with another TKI called dasatinib the alternative survival pathways were shut down, leading to more effective leukemia cell death.
- First food-grade intermediate wheatgrass released
- Make the best of bad reviews by leveraging consumer empathy
- Children’s pester power a future target for interventions
- Childhood connection to nature has many benefits but is not universally positive, finds review
- Citizen scientists help geologists to identify earthquakes and tectonic tremors